stockrow
Friday 6 November 2026
Export OSRH’s income statement to Excel — free account
OSR Health, Inc.
OSRH Healthcare Biotechnology
OSR Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 million, down 17.7% from fiscal 2024.
- Revenue
- −72.2%
- EPS
- −200.0%
- Free cash flow
- −398.8%
- Total debt
- +28.2%
Quarter to June 2026, against a year earlier
0.15
0.01
+7.14%
Follow OSRH
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 4 | 3 | 2 | (17.7%) | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | 22.98 | 20.40 | 35.29 | (2.6) pt | ||||||
| EBT | — | — | — | — | 0 | 0 | 0 | 1 | (12) | (29) | (18) | +313.8% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (336.88) | (994.16) | (974.86) | (994.2) pt | ||||||
| Net income | — | — | — | — | 0 | 0 | 0 | 0 | (10) | (27) | (15) | +308.5% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 1.64 | 0.15 | 0.06 | n/m | |||||
| Earnings | — | — | — | — | 0.00 | 0.00 | (0.02) | 0.06 | (4.79) | (0.92) | (0.40) | n/m | ||||||
| Cash flow | — | — | — | — | 0.00 | 0.00 | 0.00 | (0.11) | (0.86) | (0.22) | (0.22) | +136.5% | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.03) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | 0.00 | 0.00 | 0.00 | (0.11) | (0.86) | (0.25) | (0.22) | +142.8% | ||||||
| Book value | — | — | — | — | 0.00 | 0.00 | (0.02) | (0.51) | 66.45 | 6.51 | 3.80 | +698.9% | ||||||
| Shares, m | — | — | — | — | 8 | 2 | 2 | 8 | 2 | 20 | 28 | +19.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 7.04 | 5.00 | 2.73 | 6.0 | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.17 | 0.11 | 0.04 | 0.1 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 7.59 | 5.99 | 4.90 | 6.8 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | (14.54) | (3.66) | (1.16) | (9.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | 0 | 0 | (1) | (2) | (4) | (7) | +183.1% | |||||
| Capex | — | — | — | — | — | — | — | — | 0 | (1) | 0 | n/m | ||||||
| Free cash flow | — | — | — | — | 0 | 0 | 0 | (1) | (2) | (5) | (7) | +190.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | (1) | (1) | (2) | (1) | (14) | (13) | +123.2% | |||||
| Net debt | — | — | — | — | 0 | 0 | 0 | 0 | 2 | 3 | 4 | +61.9% | ||||||
| Shareholders’ equity | — | — | — | — | 0 | 0 | 0 | (4) | 143 | 127 | 125 | +911.5% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (0.64) | (3.67) | 2.13 | (9.75) | (10.40) | (6.10) | (10.4) pt | |||||
| ROIC | — | — | — | — | 0.00 | (66.53) | 0.00 | 0.00 | (5.03) | (8.84) | (8.19) | (8.8) pt | ||||||
| ROE | — | — | — | — | 0.00 | 733.33 | 178.79 | (20.48) | (14.83) | (13.33) | (8.13) | (13.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 21 | 4 | — | (81.0%) | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.17 | 0.73 | — | +332.1% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
OSR Health, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SKYE Skye Bioscience, Inc. | $4.6M | — (loss-making) | — | −34.71% (below 0%: shrinking) | n/m | +34.84% (above 0%: growing) | 72.71% | 0.00% | Compare |
| ADTX Aditxt, Inc. | $4.4M | — (loss-making) | — | +1,120.00% (above 0%: growing) | n/m | +60.82% (above 0%: growing) | 23.77% | (35,753.28%) | Compare |
| AZTR Azitra, Inc. | $4.4M | 1.3× | — (loss-making) | −93.38% (below 0%: shrinking) | n/m | −19.55% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| XBIO Xenetic Biosciences, Inc. | $4.4M | — (loss-making) | — (loss-making) | +11.99% (above 0%: growing) | n/m | −128.11% (below 0%: shrinking) | 100.00% | (147.09%) | Compare |
| OSRH OSR Health, Inc. | $4.1M | — (loss-making) | — | −72.20% (below 0%: shrinking) | n/m | −398.76% (below 0%: shrinking) | 27.43% | (960.69%) | |
| NCNA NuCana PLC Sponsored ADR | $4.0M | — (loss-making) | — | — | n/m | +55.66% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PMCB Nuvilex Inc. | $4.0M | — (loss-making) | — | −103.94% (below 0%: shrinking) | n/m | +60.84% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CELZ Creative Medical Technology Holdings, Inc. | $4.0M | — (loss-making) | — (loss-making) | 0.00% | n/m | −27.05% (below 0%: shrinking) | 66.67% | 0.00% | Compare |
| DRMA Dermata Therapeutics, Inc. | $3.8M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $4.2M | — | — | −17.35% | — | +22.42% | 69.69% | 0.00% |
Pay and ownership Proxy statement filed 16 July 2026
Ownership
Directors and executive officers, together
36.90%
Kuk Hyoun Hwang
36.80%
BCM Europe AG
24.30%
Bellevue Capital Management LLC
8.90%
Joint Protein Central
7.40%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement